Zhuzhou Central Hospital

Zhuzhou 412007

8 studies enrolling now · 14 studies all time

What they study most

Carcinoma, Non-Small-Cell Lung, Chronic Kidney Disease, Crohn Disease, Crohn's Disease, Interstitial Lung Diseases, Kidney Disease, Chronic, Moderately to Severely Active Crohns Disease, Moderately to Severely Active Ulcerative Colitis, Neoplasm Metastasis, Scleroderma, Systemic, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases, Systemic Sclerosis

Studies at this site

• Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer — Recruiting now
• A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis — Recruiting now
• A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases — Recruiting now
• A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer — Recruiting now
• EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) — Recruiting now
• A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease — Running, not enrolling
• A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease — Running, not enrolling
• A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease — Starting soon
• A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) — Running, not enrolling
• EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin) — Completed
• A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis — Completed